Bonus BioGroup Ltd.
BBIXF
Other OTC0.13
USD
- -
- -
ISIN
IL0004850116
Return %
Stock
S&P500
1Y
129,900.00
26.53
3Y
32,400.00
76.60
5Y
-67.50
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shai Meretzki
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Matam Advanced Technology Park Haifa Israel 31905
- IPO Date
- Jul 30, 2019
- Website
- bonusbiogroup.com
- Similar Companies
- Business
- Bonus BioGroup Ltd. is a clinical-stage biotechnology company headquartered in Haifa, Israel, specializing in the development of advanced tissue engineering and cell therapy products. The company focuses on creating next-generation regenerative medicine solutions that address severe medical conditions related to tissue damage, inflammation, and immune response. Its core product portfolio includes BonoFill, a personalized autologous tissue-engineered live-human bone graft designed for bone regeneration in maxillofacial and long bone defects, and MesenCure, an enhanced allogeneic cell therapy targeting inflammation and tissue repair, particularly for pulmonary manifestations and respiratory distress. Bonus BioGroup's products are based on proprietary technology leveraging mesenchymal cells to promote multi-functional therapeutic effects. Founded in 1981 by Dr. Shai Meretzki and a multidisciplinary team, Bonus BioGroup operates primarily in Israel but targets global clinical markets for bone and cartilage-related conditions such as arthritis, osteoporosis, and various bone and joint traumas. The company is currently advancing clinical trials for both BonoFill and MesenCure, including Phase 2 and Phase 3 stages, reflecting its commitment to addressing unmet medical needs in regenerative medicine. Recent strategic developments include a private placement completed in October 2025, raising approximately ILS 3.3 million through the issuance of shares and warrants, aimed at supporting ongoing clinical and operational activities. The company also filed confidentially to raise up to $20 million in a U.S. IPO to enhance its capital base for continued growth and expansion. Bonus BioGroup's operations encompass tissue-engineered bone graft manufacturing, cell therapy product development, and clinical research. Its innovative product offerings differentiate the company within the biotechnology sector by providing cell-based bone replacement therapies and advanced treatments for severe inflammatory and respiratory conditions. The company maintains a focus on clinical-stage development and aims to become a global leader in regenerative medicine by translating its proprietary technologies into commercially viable medical treatments. Bonus BioGroup Ltd. continues to evolve through key funding rounds, clinical advancements, and planned market expansions, underscoring its strategic direction toward becoming a front-runner in next-generation tissue regeneration technologies and cell-based therapeutic products. The company remains dedicated to leveraging its technological expertise to improve patient outcomes worldwide.